Zenitva says Sanofi-Aventis's offer falls short
This article was originally published in Scrip
Zentiva's board feels thatSanofi-Aventis's unsolicited takeover offer of CK1,050 ($60.55) per share "falls a long way short of reflecting Zentiva's fundamental value". It repeated its advice to shareholders at an extraordinary general meeting in Amsterdam on September 3rd to reject the French company's advance.
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.